{"url_path":"/sec/cik-0001900520/10-q/2026/item-6","section_key":"item-6","section_title":"Item 6 Exhibits**","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-15","source_url":"https://www.sec.gov/Archives/edgar/data/1900520/0001213900-26-057605-index.html","accession_number":"0001213900-26-057605","cik":"0001900520","ticker":null,"issuer_name":"Lomond Therapeutics Holdings, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1900520/0001213900-26-057605-index.html","primary_entity_key":"0001900520","primary_entity_name":"Lomond Therapeutics Holdings, Inc."},"word_count":772,"has_tables":true,"body_markdown":"**Item 6. Exhibits**\n\n** **\n\n**Exhibit\nNumber**\n \n**Exhibit description**\n \n**Incorporated\nby Reference\n(Form Type)**\n \n**Filing Date**\n \n**Filed\nherewith**\n\n \n \n \n \n \n \n \n \n \n\n10.1\n \n[Termination Agreement by and between Lomond Therapeutics, Inc. and Bala Therapeutics, Inc., date January 7, 2026.](https://www.sec.gov/Archives/edgar/data/1900520/000121390026003905/ea026996701ex10-1_lomond.htm)\n \n8-K\n \n1/13/2026 \n \n \n\n \n \n \n \n \n \n \n \n \n\n10.2\n \n[Amended and Restated Limited Liability Company Agreement of Idwal Therapeutics, LLC, January 8, 2026, by and between Idwal Therapeutics and the members thereof.](https://www.sec.gov/Archives/edgar/data/1900520/000121390026003908/ea027263801ex10-1_lomond.htm)\n \n8-K\n \n1/13/2026\n \n \n\n \n \n \n \n \n \n \n \n \n\n10.3\n \n[Form of Series A Preferred Unit Purchase Agreement, dated January 8, 2026, by and between Idwal Therapeutics, LLC and the Purchasers thereto.](https://www.sec.gov/Archives/edgar/data/1900520/000121390026003908/ea027263801ex10-2_lomond.htm)\n \n8-K\n \n1/13/2026 \n \n \n\n \n \n \n \n \n \n \n \n \n\n31.1 \n \n[Certification of Principal Executive Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.](ea029034801ex31-1.htm)\n \n \n \n \n \nX\n\n \n \n \n \n \n \n \n \n \n\n31.2\n \n[Certification of Principal Financial Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.](ea029034801ex31-2.htm)\n \n \n \n \n \nX\n\n \n \n \n \n \n \n \n \n \n\n32.1\n \n[Certification of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.](ea029034801ex32-1.htm)\n \n \n \n \n \n*\n\n \n \n \n \n \n \n \n \n \n\n101.INS\n \nInline XBRL Instance Document.\n \n \n \n \n \n**\n\n \n \n \n \n \n \n \n \n \n\n101.SCH\n \nInline XBRL Taxonomy Extension Schema With\nEmbedded Linkbase Documents.\n \n \n \n \n \n**\n\n \n \n \n \n \n \n \n \n \n\n101.CAL\n \nInline XBRL Taxonomy Extension Calculation\nLinkbase Document.\n \n \n \n \n \n**\n\n \n \n \n \n \n \n \n \n \n\n101.DEF\n \nInline XBRL Taxonomy Extension Definition\nLinkbase Document.\n \n \n \n \n \n**\n\n \n \n \n \n \n \n \n \n \n\n101.LAB\n \nInline XBRL Taxonomy Extension Presentation\nLinkbase Document.\n \n \n \n \n \n**\n\n \n \n \n \n \n \n \n \n \n\n101.PRE\n \nInline XBRL Taxonomy Extension Presentation\nLinkbase Document.\n \n \n \n \n \n**\n\n \n \n \n \n \n \n \n \n \n\n104\n \nCover Page Interactive Data File –\nthe cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline\nXBRL document.\n \n \n \n \n \n**\n\n \n\n*\nFurnished herewith.\n\n \n \n\n**\nThe XBRL related information in Exhibit\n101 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise\nsubject to liability of that section and shall not be incorporated by reference into any filing or other document pursuant to the\nSecurities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing or document.\n\n \n\n30\n\n \n\n \n\n**SIGNATURES**\n\n \n\nPursuant to the requirements of the Securities\nExchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.\n\n \n\n** **\n**LOMOND THERAPEUTICS HOLDINGS, INC.**\n\n \n \n \n\nDate: May 15, 2026\nBy:\n/s/\nIain Dukes\n\n \n \nIain Dukes\n\n \n \nTitle: Chief Executive\nOfficer\n\n \n \n(Principal Executive\nOfficer)\n\n \n \n \n\nDate: May 15, 2026\nBy: \n/s/\nNikolay Savchuk\n\n \n \nNikolay Savchuk\n\n \n \nTitle: President,\nChief Operating Officer\n\n \n \n(Principal Financial\nand Accounting Officer)\n\n \n\n31\n\n \n\nhttp://fasb.org/srt/2026#BoardOfDirectorsChairmanMember http://fasb.org/srt/2026#ChiefExecutiveOfficerMember http://fasb.org/srt/2026#ChiefOperatingOfficerMember http://fasb.org/srt/2026#PresidentMember\n\n0001900520\nfalse\n2026\nQ1\n--12-31\n\n0001900520\n\n2026-01-01\n2026-03-31\n\n0001900520\n\n2026-05-14\n\n0001900520\n\n2026-03-31\n\n0001900520\n\n2025-12-31\n\n0001900520\n\nus-gaap:RelatedPartyMember\n\n2026-03-31\n\n0001900520\n\nus-gaap:RelatedPartyMember\n\n2025-12-31\n\n0001900520\n\n2025-01-01\n2025-03-31\n\n0001900520\n\nus-gaap:PreferredStockMember\n\n2025-12-31\n\n0001900520\n\nus-gaap:CommonStockMember\n\n2025-12-31\n\n0001900520\n\ncik0001900520:RelatedPartyNotesReceivableMember\n\n2025-12-31\n\n0001900520\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2025-12-31\n\n0001900520\n\nus-gaap:RetainedEarningsMember\n\n2025-12-31\n\n0001900520\n\nus-gaap:PreferredStockMember\n\n2026-01-01\n2026-03-31\n\n0001900520\n\nus-gaap:CommonStockMember\n\n2026-01-01\n2026-03-31\n\n0001900520\n\ncik0001900520:RelatedPartyNotesReceivableMember\n\n2026-01-01\n2026-03-31\n\n0001900520\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2026-01-01\n2026-03-31\n\n0001900520\n\nus-gaap:RetainedEarningsMember\n\n2026-01-01\n2026-03-31\n\n0001900520\n\nus-gaap:PreferredStockMember\n\n2026-03-31\n\n0001900520\n\nus-gaap:CommonStockMember\n\n2026-03-31\n\n0001900520\n\ncik0001900520:RelatedPartyNotesReceivableMember\n\n2026-03-31\n\n0001900520\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2026-03-31\n\n0001900520\n\nus-gaap:RetainedEarningsMember\n\n2026-03-31\n\n0001900520\n\nus-gaap:PreferredStockMember\n\n2024-12-31\n\n0001900520\n\nus-gaap:CommonStockMember\n\n2024-12-31\n\n0001900520\n\ncik0001900520:RelatedPartyNotesReceivableMember\n\n2024-12-31\n\n0001900520\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2024-12-31\n\n0001900520\n\nus-gaap:RetainedEarningsMember\n\n2024-12-31\n\n0001900520\n\n2024-12-31\n\n0001900520\n\nus-gaap:PreferredStockMember\n\n2025-01-01\n2025-03-31\n\n0001900520\n\nus-gaap:CommonStockMember\n\n2025-01-01\n2025-03-31\n\n0001900520\n\ncik0001900520:RelatedPartyNotesReceivableMember\n\n2025-01-01\n2025-03-31\n\n0001900520\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2025-01-01\n2025-03-31\n\n0001900520\n\nus-gaap:RetainedEarningsMember\n\n2025-01-01\n2025-03-31\n\n0001900520\n\nus-gaap:PreferredStockMember\n\n2025-03-31\n\n0001900520\n\nus-gaap:CommonStockMember\n\n2025-03-31\n\n0001900520\n\ncik0001900520:RelatedPartyNotesReceivableMember\n\n2025-03-31\n\n0001900520\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2025-03-31\n\n0001900520\n\nus-gaap:RetainedEarningsMember\n\n2025-03-31\n\n0001900520\n\n2025-03-31\n\n0001900520\n\nus-gaap:CertificatesOfDepositMember\nus-gaap:CashEquivalentsMember\n\n2026-01-01\n2026-03-31\n\n0001900520\n\nus-gaap:CertificatesOfDepositMember\nus-gaap:CashEquivalentsMember\n\n2025-01-01\n2025-03-31\n\n0001900520\n\nus-gaap:StockOptionMember\n\n2026-01-01\n2026-03-31\n\n0001900520\n\nus-gaap:StockOptionMember\n\n2025-01-01\n2025-03-31\n\n0001900520\n\ncik0001900520:PlacementAgentWarrantsMember\n\n2026-01-01\n2026-03-31\n\n0001900520\n\ncik0001900520:PlacementAgentWarrantsMember\n\n2025-01-01\n2025-03-31\n\n0001900520\n\nus-gaap:PrivatePlacementMember\n\n2026-01-01\n2026-03-31\n\n0001900520\n\nus-gaap:CommonStockMember\nus-gaap:PrivatePlacementMember\n\n2025-01-24\n2025-01-24\n\n0001900520\n\ncik0001900520:OfferingPriceMember\n\n2025-01-24\n2025-01-24\n\n0001900520\n\nus-gaap:CommonStockMember\nus-gaap:PrivatePlacementMember\n\n2025-03-24\n2025-03-24\n\n0001900520\n\ncik0001900520:OfferingPriceMember\n\n2025-03-24\n2025-03-24\n\n0001900520\n\ncik0001900520:PlacementAgentWarrantsMember\n\n2025-03-24\n\n0001900520\n\ncik0001900520:PlacementAgentWarrantsMember\nus-gaap:CommonStockMember\n\n2025-03-24\n\n0001900520\n\ncik0001900520:PlacementAgentWarrantsMember\nus-gaap:CommonStockMember\n\n2025-03-24\n2025-03-24\n\n0001900520\n\ncik0001900520:PromissoryNoteMember\ncik0001900520:LegacyLomondMember\n\n2024-09-01\n2024-09-30\n\n0001900520\n\ncik0001900520:PromissoryNoteMember\ncik0001900520:EileanAUMember\n\n2026-01-01\n2026-03-31\n\n0001900520\n\ncik0001900520:PromissoryNoteMember\ncik0001900520:EileanAUMember\n\n2025-01-01\n2025-12-31\n\n0001900520\n\ncik0001900520:EileanAUMember\n\n2026-01-01\n2026-03-31\n\n0001900520\n\ncik0001900520:EileanAUMember\n\n2025-02-20\n2025-02-20\n\n0001900520\n\ncik0001900520:AbetSolutionsAbetMember\n\n2026-01-01\n2026-03-31\n\n0001900520\n\ncik0001900520:PromissoryNoteMember\ncik0001900520:EilLicenseAgreementMember\n\n2024-10-01\n2024-10-31\n\n0001900520\n\ncik0001900520:PromissoryNoteMember\ncik0001900520:BalaLicenseAgreementMember\n\n2024-10-01\n2024-10-31\n\n0001900520\n\ncik0001900520:PromissoryNoteMember\n\n2024-10-01\n2024-10-31\n\n0001900520\n\ncik0001900520:PromissoryNoteMember\ncik0001900520:EilAndBalaMember\n\n2026-01-01\n2026-03-31\n\n0001900520\n\ncik0001900520:PromissoryNoteMember\ncik0001900520:EilAndBalaMember\n\n2025-01-01\n2025-03-31\n\n0001900520\n\ncik0001900520:PromissoryNoteMember\ncik0001900520:BalaLicenseAgreementMember\n\n2026-01-07\n2026-01-07\n\n0001900520\n\n2026-01-07\n2026-01-07\n\n0001900520\n\ncik0001900520:BalaLicenseAgreementMember\n\n2026-01-07\n2026-01-07\n\n0001900520\n\ncik0001900520:BalaLicenseAgreementMember\n\n2026-01-07\n\n0001900520\n\ncik0001900520:PromissoryNoteMember\ncik0001900520:LegacyLomondMember\n\n2026-01-01\n2026-03-31\n\n0001900520\n\ncik0001900520:PromissoryNoteMember\ncik0001900520:LegacyLomondMember\n\n2025-01-01\n2025-03-31\n\n0001900520\n\n2024-11-01\n2024-11-01\n\n0001900520\n\ncik0001900520:DrDukesMember\n\n2024-11-01\n2024-11-01\n\n0001900520\n\ncik0001900520:DrSavchukMember\n\n2024-11-01\n2024-11-01\n\n0001900520\n\ncik0001900520:ConsultingAgreementsMember\n\n2026-01-01\n2026-03-31\n\n0001900520\n\ncik0001900520:ConsultingAgreementsMember\n\n2025-01-01\n2025-03-31\n\n0001900520\n\ncik0001900520:ResearchandDevelopmentExpensesMember\ncik0001900520:OfficerConsultantsMember\n\n2026-01-01\n2026-03-31\n\n0001900520\n\ncik0001900520:ResearchandDevelopmentExpensesMember\ncik0001900520:OfficerConsultantsMember\n\n2025-01-01\n2025-03-31\n\n0001900520\n\ncik0001900520:GeneralAndAdministrativeExpenseaMember\ncik0001900520:OfficerConsultantsMember\n\n2026-01-01\n2026-03-31\n\n0001900520\n\ncik0001900520:GeneralAndAdministrativeExpensesMember\ncik0001900520:OfficerConsultantsMember\n\n2025-01-01\n2025-03-31\n\n0001900520\n\nus-gaap:StockOptionMember\n\n2024-09-19\n2024-09-19\n\n0001900520\n\nus-gaap:StockOptionMember\n\n2026-01-01\n2026-03-31\n\n0001900520\n\ncik0001900520:ResearchAndDevelopmentExpensesMember\n\n2026-01-01\n2026-03-31\n\n0001900520\n\ncik0001900520:ResearchAndDevelopmentExpensesMember\n\n2025-01-01\n2025-03-31\n\n0001900520\n\ncik0001900520:TwoZeroTwoFourStockPlanAndGrantOfOptionsMember\n\n2026-01-01\n2026-03-31\n\n0001900520\n\nus-gaap:RelatedPartyMember\n\n2026-01-01\n2026-03-31\n\n0001900520\n\nus-gaap:RelatedPartyMember\n\n2025-01-01\n2025-03-31\n\n0001900520\n\ncik0001900520:BalaCommonStockMember\n\n2026-01-07\n\n0001900520\n\n2026-01-07\n\n0001900520\n\ncik0001900520:BalaCommonStockMember\n\n2026-03-31\n\n0001900520\n\n2026-01-08\n\n0001900520\n\ncik0001900520:DelawareLimitedLiabilityCompanyMember\n\n2026-01-08\n\n0001900520\n\ncik0001900520:IdwalTherapeuticsLLCMember\n\n2026-03-31\n\n0001900520\n\ncik0001900520:TwoZeroTwoFourStockPlanAndGrantOfOptionsMember\n\n2026-03-31\n\n0001900520\n\ncik0001900520:LegacyLomondStockPlanMember\n\n2026-01-01\n2026-03-31\n\n0001900520\n\ncik0001900520:GeneralAndAdministrativeExpensesMember\n\n2026-01-01\n2026-03-31\n\n0001900520\n\ncik0001900520:TwoZeroTwoFourStockPlanAndGrantOfOptionsMember\n\n2025-01-01\n2025-03-31\n\n0001900520\n\ncik0001900520:GeneralAndAdministrativeExpensesMember\n\n2025-01-01\n2025-03-31\n\n0001900520\n\n2025-12-30\n\n0001900520\n\n2025-12-31\n2025-12-31\n\nxbrli:shares\n\niso4217:USD\n\niso4217:USD\n\nxbrli:shares\n\ncik0001900520:Segment\n\nxbrli:pure"}